Skip to main content
Top
Published in: Tumor Biology 1/2016

01-01-2016 | Research Article

Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer

Authors: Xiaoxiao Zuo, Ling Chen, Lifeng Liu, Zhe Zhang, Xiaojin Zhang, Qing Yu, Lu Feng, Xinhan Zhao, Tianjie Qin

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

Currently, there is no effective single antigen and there are only a very limited number of complex antigens for the diagnosis of early-stage breast cancer (BC). In this study, we used serological analysis of recombinant cDNA expression libraries (SEREX) in combination with phage display technology to screen complex autoantigens from the sera of BC patients. The cDNA expression library was constructed using tissue samples of three patients with BC at as early as stage T1N0M0. The serum samples of ten patients, including the three patients who provided tissue samples, as well as five healthy human subjects as controls were used to screen the library. All seven autoantigens were identified from the library by four rounds of screening and matched the existing genes after a blast search using NCBI-BLAST. Then, the expression conditions of the autoantibodies of the seven autoantigens and anti-CA15-3 in the sera from 100 BC patients and 50 healthy donors were examined by gray values. The data were analyzed by the area under the receiver operating characteristic (ROC) curve and logistic regression diagnostic models. In the end, a panel of complex autoantigens consisting of B11 (LGALS3), B18 (PHB2), B119 (MUC1), B130 (GK2), and CA15-3, which had a sensitivity of 87 % and a specificity of 76 %, were identified. The area under the curve (AUC) of the complex antigens was 0.872, which is significantly greater than that of anti-CA15-3 alone (AUC = 0.634) for the diagnosis of BC. Thus, this panel of complex antigens provides a promising strategy for the diagnosis of early-stage BC.
Literature
1.
go back to reference Chourb S, Mackness BC, Farris LR, McDonald MJ. Improved detection of the MUC1 cancer antigen CA 15-3 by ALYGNSA fluorimmunoassay. Health. 2011;3:1949–4998.CrossRef Chourb S, Mackness BC, Farris LR, McDonald MJ. Improved detection of the MUC1 cancer antigen CA 15-3 by ALYGNSA fluorimmunoassay. Health. 2011;3:1949–4998.CrossRef
2.
go back to reference Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. International journal of proteomics 2011, 2011. Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. International journal of proteomics 2011, 2011.
3.
go back to reference Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res. 2004;24:3221–4.PubMed Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res. 2004;24:3221–4.PubMed
4.
go back to reference Atahan K, Küpeli H, Gür S, Yiğitbaşı T, Baskın Y, Yiğit S, et al. The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer. Int J Med Sci. 2011;8:148.CrossRefPubMedPubMedCentral Atahan K, Küpeli H, Gür S, Yiğitbaşı T, Baskın Y, Yiğit S, et al. The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer. Int J Med Sci. 2011;8:148.CrossRefPubMedPubMedCentral
5.
go back to reference Dong X, Yang M, Sun H, Lu J, Zheng Z, Li Z, et al. Combined measurement of CA 15-3 with novel autoantibodies improves diagnostic accuracy for breast cancer. Onco Targets Ther. 2013;6:273–9.PubMedPubMedCentral Dong X, Yang M, Sun H, Lu J, Zheng Z, Li Z, et al. Combined measurement of CA 15-3 with novel autoantibodies improves diagnostic accuracy for breast cancer. Onco Targets Ther. 2013;6:273–9.PubMedPubMedCentral
6.
go back to reference Wang Y, Balan V, Gao X, Reddy PG, Kho D, Tait L, et al. The significance of galectin-3 as a new basal cell marker in prostate cancer. Cell Death Dis. 2013;4:e753.CrossRefPubMedPubMedCentral Wang Y, Balan V, Gao X, Reddy PG, Kho D, Tait L, et al. The significance of galectin-3 as a new basal cell marker in prostate cancer. Cell Death Dis. 2013;4:e753.CrossRefPubMedPubMedCentral
7.
go back to reference Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, et al. Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget. 2013;4:542–9.CrossRefPubMedPubMedCentral Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, et al. Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget. 2013;4:542–9.CrossRefPubMedPubMedCentral
8.
go back to reference Al-Salam S, Al-Salam M, Al AM. Galectin-3: a novel protein in cerebellar hemangioblastoma. Int J Clin Exp Pathol. 2013;6:853–61.PubMedPubMedCentral Al-Salam S, Al-Salam M, Al AM. Galectin-3: a novel protein in cerebellar hemangioblastoma. Int J Clin Exp Pathol. 2013;6:853–61.PubMedPubMedCentral
9.
go back to reference Righi A, Morandi L, Leonardi E, Farnedi A, Marucci G, Sisto A, et al. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior. Hum Pathol. 2013;44:2400–9.CrossRefPubMed Righi A, Morandi L, Leonardi E, Farnedi A, Marucci G, Sisto A, et al. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior. Hum Pathol. 2013;44:2400–9.CrossRefPubMed
10.
go back to reference Dawson H, Andre S, Karamitopoulou E, Zlobec I, Gabius HJ. The growing galectin network in colon cancer and clinical relevance of cytoplasmic galectin-3 reactivity. Anticancer Res. 2013;33:3053–9.PubMed Dawson H, Andre S, Karamitopoulou E, Zlobec I, Gabius HJ. The growing galectin network in colon cancer and clinical relevance of cytoplasmic galectin-3 reactivity. Anticancer Res. 2013;33:3053–9.PubMed
11.
go back to reference Mazurek N, Byrd JC, Sun Y, Ueno S, Bresalier RS. A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells. Cancer. 2011;117:4375–80.CrossRefPubMedPubMedCentral Mazurek N, Byrd JC, Sun Y, Ueno S, Bresalier RS. A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells. Cancer. 2011;117:4375–80.CrossRefPubMedPubMedCentral
12.
go back to reference Lee MH, Lin L, Equilibrina I, Uchiyama S, Matsunaga S, Fukui K. ASURA (PHB2) is required for kinetochore assembly and subsequent chromosome congression. Acta Histochem Cytochem. 2011;44:247–58.CrossRefPubMedPubMedCentral Lee MH, Lin L, Equilibrina I, Uchiyama S, Matsunaga S, Fukui K. ASURA (PHB2) is required for kinetochore assembly and subsequent chromosome congression. Acta Histochem Cytochem. 2011;44:247–58.CrossRefPubMedPubMedCentral
14.
go back to reference Zhang Y, Wang Y, Xiang Y, Lee W, Zhang Y. Prohibitins are involved in protease-activated receptor 1-mediated platelet aggregation. J Thromb Haemost. 2012;10:411–8.CrossRefPubMed Zhang Y, Wang Y, Xiang Y, Lee W, Zhang Y. Prohibitins are involved in protease-activated receptor 1-mediated platelet aggregation. J Thromb Haemost. 2012;10:411–8.CrossRefPubMed
15.
go back to reference Cheng J, Gao F, Chen X, Wu J, Xing C, Lv Z, Xu W, Xie Q, Wu L, Ye S, Xie H, Zheng S, Zhou L. Prohibitin-2 promotes hepatocellular carcinoma malignancy progression in hypoxia based on a label-free quantitative proteomics strategy. MolCarcinog 2013. Cheng J, Gao F, Chen X, Wu J, Xing C, Lv Z, Xu W, Xie Q, Wu L, Ye S, Xie H, Zheng S, Zhou L. Prohibitin-2 promotes hepatocellular carcinoma malignancy progression in hypoxia based on a label-free quantitative proteomics strategy. MolCarcinog 2013.
16.
go back to reference Jager D, Filonenko V, Gout I, Frosina D, Eastlake-Wade S, Castelli S, et al. NY-BR-1 is a differentiation antigen of the mammary gland. Appl Immunohistochem Mol Morphol. 2007;15:77–83.CrossRefPubMed Jager D, Filonenko V, Gout I, Frosina D, Eastlake-Wade S, Castelli S, et al. NY-BR-1 is a differentiation antigen of the mammary gland. Appl Immunohistochem Mol Morphol. 2007;15:77–83.CrossRefPubMed
Metadata
Title
Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer
Authors
Xiaoxiao Zuo
Ling Chen
Lifeng Liu
Zhe Zhang
Xiaojin Zhang
Qing Yu
Lu Feng
Xinhan Zhao
Tianjie Qin
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3932-y

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine